Overview
Joseph W. Turek, MD, PhD, MBA is an academic pediatric cardiac surgeon at Duke University in Durham, North Carolina. Since 2017, Dr. Turek has served as chief of pediatric cardiac surgery. Prior to Duke, he served in a similar leadership role at the University of Iowa Stead Family Children’s Hospital from 2012-2017.
Dr. Turek attended the Illinois Mathematics and Science Academy for secondary education. He then graduated from Northwestern University with a degree in biochemistry and received his MD/PhD (pharmacology) from the University of Illinois in Chicago with Alpha Omega Alpha distinction. He completed his general surgery education at Duke University, where he also finished a cardiothoracic surgery residency. During this time, he served as a visiting congenital heart surgery fellow at Texas Children’s Hospital. Dr. Turek completed a congenital cardiac surgery fellowship at the Children’s Hospital of Philadelphia in 2011. He received his MBA with a concentration in Health Sector Management from Duke’s Fuqua School of Business in 2020.
Board certified in general surgery, thoracic surgery and congenital cardiac surgery, Dr. Turek has been one of the foremost innovators of the last decade in congenital heart surgery, developing novel operations, modifying techniques and introducing new products and procedures to children and adults with congenital cardiac disease. Most notably, he performed the world’s first co-transplant of a heart and cultured thymus tissue, in an operation that could usher in an era in which solid organ transplant recipients can develop tolerance to their newly transplanted organ, recognizing them as “self”. In another highly innovative operation, he performed the world’s first partial heart transplant for a newborn without functioning aortic or pulmonary valves, maintaining growth capacity of the newly implanted valves. Additionally, he led the team at Duke in completing the nation’s first pediatric donation after circulatory death heart transplant with ex vivo reanimation and with normothermic regional perfusion, as a means to expand the already limited donor pool of available organs. His clinical passion and expertise lies in high complexity neonatal heart surgery.
Academically, Dr. Turek has published over 200 peer-reviewed manuscripts and numerous book chapters. He maintains an active and well-funded research laboratory with projects spanning from basic science to translational to clinical research, in areas such as heart transplant tolerance with thymus-heart co-transplant, partial heart transplantation, xenotransplantation, Marfan syndrome, and the role of alpha-gal sensitization in biologic valve degradation. He maintains active leadership roles in national and international cardiothoracic surgery societies.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Kidney transplantation using a pediatric en bloc graft after normothermic regional perfusion and donation after circulatory death procurement.
Journal Article Am J Transplant · December 2025 Kidney transplantation is the ultimate treatment for patients with end stage renal disease. However, with the expanding gap between organ supply and demand, utilization of organs from extended-criteria donors is an important strategy to address this proble ... Full text Link to item CitePreoperative ECMO: Building Bridges.
Journal Article Ann Thorac Surg · December 2025 Full text Link to item CiteReconstitution of thymopoiesis via implantation of cryopreserved cultured thymus tissue into athymic recipients.
Journal Article Am J Transplant · November 13, 2025 Implantation of cultured allogeneic thymus tissue (CTTI) into athymic human recipients generates functional recipient-derived naïve T cells that are tolerant to the donor. Currently, CTTI is always performed with 12 to 21 days of thymus procurement to avoi ... Full text Link to item CiteRecent Grants
Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Pivotal Study - Pro00115068
Clinical TrialPrincipal Investigator · Awarded by Autus Valve Technologies, Inc. · 2024 - 2034Tolerance to Allogeneic Hearts via Implantation of Cultured Donor Thymus
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2028Project Addendum #2
ResearchPrincipal Investigator · Awarded by Revivicor, Inc · 2025 - 2026View All Grants